{
    "name": "interferon alfa 2b",
    "comment": "Rx",
    "other_names": [
        "Intron A",
        "Interferon alfa-2b"
    ],
    "classes": [
        "Biological Response Modifiers",
        "Hepatitis B/Hepatitis C Agents"
    ],
    "source": "https://reference.medscape.com/drug/intron-a-interferon-alfa-2b-interferon-alfa-2b-342615",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: unknown"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: unknown"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Alfa interferons cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders",
                "The risk of serious depression, with suicidal ideation and completed suicides, and other serious neuropsychiatric disorders are increased with alpha interferons",
                "Discontinue drug if persistently severe or worsening signs or symptoms of the above conditions are present; disorders typically resolve after stopping therapy",
                "These disorders may not resolve after the drug is discontinued",
                "Monitored closely with periodic clinical and laboratory evaluations"
            ],
            "specific": [
                {
                    "type": "Combination therapy with ribavirin",
                    "description": [
                        "Ribavirin may cause birth defects and/or fetal death",
                        "Extreme care must be taken to avoid pregnancy in women taking peginterferon alfa-2a and in female partners of men taking peginterferon alfa-2a",
                        "Ribavirin causes hemolytic anemia; associated anemia may result in worsening of cardiac disease",
                        "Because ribavirin is genotoxic and mutagenic, consider it a potential carcinogen"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Autoimmune hepatitis",
                "Decompensated liver disease (Child-Pugh >6 [class B and C])"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Life-threatening or fatal neuropsychiatric events, including suicide, suicidal and homicidal ideation, depression, relapse of drug addiction/overdose, and aggressive behavior sometimes directed towards others reported in patients with and without a previous psychiatric disorder during therapy and follow-up; psychoses, hallucinations, bipolar disorders, and mania have been observed in patients treated with interferon alpha should be used with caution in patients with a history of psychiatric disorders; discontinue if severe depression develops",
                "If psychiatric symptoms persist or worsen, or suicidal or homicidal ideation or aggressive behavior towards others identified, discontinue therapy and follow patient closely, with psychiatric intervention as appropriate; narcotics, hypnotics, or sedatives may be used concurrently with caution and patients should be closely monitored until adverse effects resolved",
                "Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension, and sarcoidosis, some resulting in respiratory failure or patient deaths, may be induced or aggravated by therapy; recurrence of respiratory failure has been observed with interferon rechallenge; monitor",
                "Development or exacerbation of autoimmune disorders (e.g., thyroiditis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, and psoriasis) observed; use with caution in patients with autoimmune disorders",
                "Caution in pre-existing cardiac abnormalities &/or advanced cancer Ischemic and hemorrhagic cerebrovascular events reported",
                "Pancreatitis and ulcerative or hemorrhagic/iscemic colitis may occur",
                "Severe decreases in neutrophil or platelet counts reported",
                "Hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including peginterferon alpha 2b; cirrhotic CHC patients co-infected with HIV receiving highly active antiretroviral therapy (HAART) and alpha interferons with or without ribavirin appear to be at increased risk for development of hepatic decompensation compared to patients not receiving HAART; monitor clinical status and hepatic function during treatment and discontinue immediately if decompensation (Child-Pugh score greater than 6) observed",
                "Monitor patients with impaired renal function, for signs and symptoms of interferon toxicity, including increases in serum creatinine; adjust dose or discontinue therapy accordingly",
                "Serious, acute hypersensitivity reactions and cutaneous eruptions reported",
                "Dental/periodontal disorders reported with combination therapy Hypertriglyceridemia may result in pancreatitis (e.g., triglycerides greater than 1000 mg/dL)",
                "Weight loss and growth inhibition reported during combination therapy in pediatric patients",
                "Long-term growth inhibition (height) reported in some patients",
                "Peripheral neuropathy observed when used in combination with telbivudine",
                "Risk of visual impairment and retinal disorders; discontinue if ophthalmologic problems develop",
                "Use with caution in patients with endocrine disorder: thyroid disease; DM prone to ketoacidosis",
                "Pre-existing cardiac abnormalities &/or advanced cancer",
                "AIDS-related Kaposi's Sarcoma: do not use in patients w/ rapidly progressive disease",
                "Discontinue if acute hypersensitivity occurs",
                "Risk of exacerbation of preexisting psoriasis & sarcoidosis; risk of developing new sarcoidosis",
                "Patients should be well hydrated during initial treatment",
                "If platelets <50,000/mmÂ³, do not administer IM (may admin SC)",
                "Do not use the 18 million IU or 50 million IU powder for injection or the18 million IU multidose vial for condylomata acuminata",
                "Increases risk of hepatic decompensation and death in patients with cirrhosis; any patient developing liver function abnormalities during treatment should be monitored closely and if appropriate, treatment should be discontinued",
                "Numerous cardiotoxicities, including arrhythmias, ischemia, infarction, and cardiomyopathy occur during and immediately after infusion"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "deferiprone, interferon alfa 2b.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of interferon alfa 2b by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "interferon alfa 2b and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "interferon alfa 2b, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, interferon alfa 2b.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, interferon alfa 2b.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "interferon alfa 2b, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Cutaneous vasculitic toxicities (eg, vasculitic ulcerations and gangrene) were reported during therapy with hydroxyurea in patients with a history of, or currently receiving, interferon therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lamivudine",
            "description": {
                "common": "interferon alfa 2b, lamivudine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of liver decompensation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and interferon alfa 2b both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and interferon alfa 2b both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "interferon alfa 2b increases levels of theophylline by decreasing metabolism. Use Caution/Monitor. Greater risk of interaction in smokers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled and interferon alfa 2b both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and interferon alfa 2b both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "interferon alfa 2b increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zidovudine",
            "description": {
                "common": "interferon alfa 2b increases levels of zidovudine by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "shark cartilage",
            "description": {
                "common": "interferon alfa 2b, shark cartilage.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Enhanced anti angiogenesis (theoretical interaction)."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "8-96"
        },
        {
            "name": "Fever",
            "percent": "34-94"
        },
        {
            "name": "Neutropenia",
            "percent": "92"
        },
        {
            "name": "Flu",
            "percent": "79"
        },
        {
            "name": "like syndrome",
            "percent": "28-75"
        },
        {
            "name": "Myalgia",
            "percent": "1-69"
        },
        {
            "name": "Anorexia",
            "percent": "68"
        },
        {
            "name": "Leukopenia",
            "percent": "17-66"
        },
        {
            "name": "Nausea",
            "percent": "13-63"
        },
        {
            "name": "Transaminases increased",
            "percent": "63"
        },
        {
            "name": "Weakness",
            "percent": "21-62"
        },
        {
            "name": "Headache",
            "percent": "54"
        },
        {
            "name": "Chills",
            "percent": "2-45"
        },
        {
            "name": "Diarrhea",
            "percent": "42"
        },
        {
            "name": "Rigors",
            "percent": "40"
        },
        {
            "name": "Depression",
            "percent": "38"
        },
        {
            "name": "up to",
            "percent": "34"
        },
        {
            "name": "of pts",
            "percent": "33"
        },
        {
            "name": "suicidal ideation",
            "percent": "2-32"
        },
        {
            "name": "attempts",
            "percent": "32"
        },
        {
            "name": "suicide",
            "percent": "31"
        },
        {
            "name": "Alopecia",
            "percent": "31"
        },
        {
            "name": "Dyspnea",
            "percent": "28"
        },
        {
            "name": "Somnolence",
            "percent": "28"
        },
        {
            "name": "Vomiting",
            "percent": "25"
        },
        {
            "name": "Anemia",
            "percent": "24"
        },
        {
            "name": "Cough",
            "percent": "24"
        },
        {
            "name": "Pharyngitis",
            "percent": "1-23"
        },
        {
            "name": "Chest pain",
            "percent": "22"
        },
        {
            "name": "Xerostomia",
            "percent": "21"
        },
        {
            "name": "Rash",
            "percent": "21"
        },
        {
            "name": "Dizziness",
            "percent": "1-21"
        },
        {
            "name": "Taste alteration",
            "percent": "1-21"
        },
        {
            "name": "Abdominal pain",
            "percent": "19"
        },
        {
            "name": "Irritability",
            "percent": "18"
        },
        {
            "name": "Sinusitis",
            "percent": "17"
        },
        {
            "name": "Skeletal pain",
            "percent": "15"
        },
        {
            "name": "Diaphoresisi",
            "percent": "14"
        },
        {
            "name": "Paresthesias",
            "percent": "14"
        },
        {
            "name": "Arthralgia",
            "percent": "14"
        },
        {
            "name": "back pain",
            "percent": "14"
        },
        {
            "name": "Pain",
            "percent": "14"
        },
        {
            "name": "Moniliasis",
            "percent": "1-13"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "12"
        },
        {
            "name": "Amnesia",
            "percent": "12"
        },
        {
            "name": "Constipation",
            "percent": "12"
        },
        {
            "name": "Gingivitis",
            "percent": "12"
        },
        {
            "name": "Impaired concentration",
            "percent": "11"
        },
        {
            "name": "Malaise",
            "percent": "10"
        },
        {
            "name": "Weight loss",
            "percent": "10"
        },
        {
            "name": "Amenorrhea",
            "percent": "10"
        },
        {
            "name": "BUN increased",
            "percent": "10"
        },
        {
            "name": "Confusion",
            "percent": "10"
        },
        {
            "name": "Insomnia",
            "percent": "10"
        },
        {
            "name": "Iruritus",
            "percent": "10"
        },
        {
            "name": "Bronchitis",
            "percent": "9"
        },
        {
            "name": "Dry skin",
            "percent": "9"
        },
        {
            "name": "Edema",
            "percent": "8"
        },
        {
            "name": "Hypoestheisa",
            "percent": "8"
        },
        {
            "name": "Loose stools",
            "percent": "8"
        },
        {
            "name": "Nasal congestion",
            "percent": "7"
        },
        {
            "name": "Polyuria",
            "percent": "7"
        },
        {
            "name": "Anxiety",
            "percent": "6"
        },
        {
            "name": "Hypertension",
            "percent": "5"
        },
        {
            "name": "Dermatitis",
            "percent": "5"
        },
        {
            "name": "Dyspepsia",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Agitation",
            "percent": null
        },
        {
            "name": "Infection",
            "percent": null
        },
        {
            "name": "SCr increased",
            "percent": null
        },
        {
            "name": "Herpes virus infections",
            "percent": null
        },
        {
            "name": "UTI",
            "percent": null
        },
        {
            "name": "Acute hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "exacerbation of preexisting psoriasis",
            "percent": null
        },
        {
            "name": "sarcoidosis",
            "percent": null
        },
        {
            "name": "Myelosuppression",
            "percent": null
        },
        {
            "name": "thyroid dysfunction",
            "percent": null
        },
        {
            "name": "hepatotox",
            "percent": null
        },
        {
            "name": "pulmonary infiltrates",
            "percent": null
        },
        {
            "name": "retinal hemorrhage",
            "percent": null
        },
        {
            "name": "Severe cytopenias incl aplastic anemia",
            "percent": null
        },
        {
            "name": "Autoimmune dz",
            "percent": null
        },
        {
            "name": "DM",
            "percent": null
        },
        {
            "name": "hyperglycemia",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        },
        {
            "name": "Pulmonary fibrosis",
            "percent": null
        },
        {
            "name": "Hepatitis B virus reactivation in HCV",
            "percent": null
        },
        {
            "name": "HBV co",
            "percent": null
        },
        {
            "name": "infected patients",
            "percent": null
        },
        {
            "name": "Pericarditis",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        },
        {
            "name": "Tongue pigmentation",
            "percent": null
        }
    ]
}